Biohaven flunks first clinical test for rare disease drug post-Pfizer sell-offnews2022-05-23T14:16:00+00:00May 23rd, 2022|FierceBiotech|
Chasing Lilly and Pfizer, Concert’s JAK inhibitor hits high notes in phase 3 alopecia trialnews2022-05-23T12:41:12+00:00May 23rd, 2022|FierceBiotech|
J&J’s $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potentialnews2022-05-23T09:29:38+00:00May 23rd, 2022|FierceBiotech|
Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public attacknews2022-05-20T14:53:19+00:00May 20th, 2022|FierceBiotech|
Not an ‘excellent outcome’ for Athersys stock as stem cell therapy misses endpoint in Japanese trialnews2022-05-20T13:45:41+00:00May 20th, 2022|FierceBiotech|
100% overall survival data for gene therapy fuel Rocket for flight to regulatorsnews2022-05-20T13:41:13+00:00May 20th, 2022|FierceBiotech|
Terremoto spells out plan to expand covalent drug alphabet with $75M fundingnews2022-05-20T11:33:54+00:00May 20th, 2022|FierceBiotech|
Death triggers FDA hold on Foghorn blood cancer clinical trial, shrouding timing of data dropnews2022-05-20T10:15:54+00:00May 20th, 2022|FierceBiotech|
Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient deathnews2022-05-20T09:17:15+00:00May 20th, 2022|FierceBiotech|
Pfizer’s Arena goal? Get out of the way and don’t ‘break the new toy’news2022-05-19T19:44:34+00:00May 19th, 2022|FierceBiotech|
